Zosano Pharma Stock Forecast, Price & News

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zosano Pharma in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Zosano Pharma stock.
View analyst ratings for Zosano Pharma or view top-rated stocks.

Wall Street analysts have given Zosano Pharma a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Zosano Pharma wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Zosano Pharma saw a decrease in short interest in the month of August. As of August 31st, there was short interest totaling 4,910,000 shares, a decrease of 25.4% from the August 15th total of 6,580,000 shares. Based on an average daily trading volume, of 1,290,000 shares, the short-interest ratio is currently 3.8 days. Approximately 7.2% of the company's shares are short sold.
View Zosano Pharma's Short Interest.

Zosano Pharma is scheduled to release its next quarterly earnings announcement on Friday, November 12th 2021.
View our earnings forecast for Zosano Pharma.

Zosano Pharma Co. (NASDAQ:ZSAN) announced its quarterly earnings results on Monday, August, 9th. The biotechnology company reported ($0.06) EPS for the quarter, beating analysts' consensus estimates of ($0.08) by $0.02.
View Zosano Pharma's earnings history.

Zosano Pharma's stock was trading at $0.5662 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, ZSAN stock has increased by 28.9% and is now trading at $0.73.
View which stocks have been most impacted by COVID-19.

Shares of Zosano Pharma reverse split on Friday, January 26th 2018. The 1-20 reverse split was announced on Thursday, January 25th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, January 25th 2018. An investor that had 100 shares of Zosano Pharma stock prior to the reverse split would have 5 shares after the split.

3 Wall Street analysts have issued 1 year price objectives for Zosano Pharma's stock. Their forecasts range from $2.00 to $2.50. On average, they anticipate Zosano Pharma's share price to reach $2.17 in the next twelve months. This suggests a possible upside of 196.8% from the stock's current price.
View analysts' price targets for Zosano Pharma or view top-rated stocks among Wall Street analysts.

Some companies that are related to Zosano Pharma include Molecular Templates (MTEM), Verrica Pharmaceuticals (VRCA), Immutep (IMMP), Athersys (ATHX), Cogent Biosciences (COGT), Angion Biomedica (ANGN), Viracta Therapeutics (VIRX), Infinity Pharmaceuticals (INFI), KemPharm (KMPH), Syros Pharmaceuticals (SYRS), Flexion Therapeutics (FLXN), 9 Meters Biopharma (NMTR), Taiwan Liposome (TLC), Citius Pharmaceuticals (CTXR) and MEI Pharma (MEIP).
View all of ZSAN's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Zosano Pharma investors own include Aeterna Zentaris (AEZS), Pennsylvania Real Estate Investment Trust (PEI), Bionano Genomics (BNGO), Gran Tierra Energy (GTE), Cannabics Pharmaceuticals (CNBX), Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Novan (NOVN), Hallador Energy (HNRG) and EnLink Midstream (ENLC).

(ZSAN) raised $47 million in an initial public offering on Tuesday, January 27th 2015. The company issued 4,300,000 shares at a price of $10.00-$12.00 per share. Ladenburg Thalmann and Roth Capital Partners served as the underwriters for the IPO.

Zosano Pharma trades on the NASDAQ under the ticker symbol "ZSAN."

Zosano Pharma's stock is owned by many different retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (3.96%), BlackRock Inc. (1.91%), Renaissance Technologies LLC (1.17%), Geode Capital Management LLC (0.83%), GSA Capital Partners LLP (0.82%) and State Street Corp (0.36%). Company insiders that own Zosano Pharma stock include Deirdre Mary Bigley, Hayley Lewis and Steven Lo.
View institutional ownership trends for Zosano Pharma.

ZSAN stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., and Citadel Advisors LLC. Company insiders that have sold Zosano Pharma company stock in the last year include Deirdre Mary Bigley, Hayley Lewis, and Steven Lo.
View insider buying and selling activity for Zosano Pharma or view top insider-selling stocks.

ZSAN stock was purchased by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, GSA Capital Partners LLP, State Street Corp, Vanguard Group Inc., Virtu Financial LLC, Geode Capital Management LLC, Millennium Management LLC, and Telemetry Investments L.L.C..
View insider buying and selling activity for Zosano Pharma or or view top insider-buying stocks.

Shares of ZSAN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ZSAN stock can currently be purchased for approximately $0.73.

Zosano Pharma has a market capitalization of $84.38 million and generates $220,000.00 in revenue each year. The biotechnology company earns $-33,370,000.00 in net income (profit) each year or ($0.49) on an earnings per share basis.

Zosano Pharma employs 45 workers across the globe.

The official website for Zosano Pharma is www.zosanopharma.com.

Zosano Pharma is headquartered at 34790 ARDENTECH COURT, FREMONT CA, 94555.

Zosano Pharma's mailing address is 34790 ARDENTECH COURT, FREMONT CA, 94555. The biotechnology company can be reached via phone at (510) 745-1200 or via email at [email protected].